mergers_acquisitions

Indianapolis – September 13, 2026 -- Corteva (NYSE: CTVA) and Belgium-based Globachem N.V. have signed a definitive agreement to launch a 50/50 joint venture aimed at developing and delivering new crop protection solutions for farmers in Europe and the Americas, with the deal expected to close in the fourth quarter of 2026.

Joint venture will pool late-stage pipeline technology from both parent companies

The independently operated JV will draw on late-pipeline to commercial-stage technology from Corteva and Globachem to develop, register and market new products. Resulting solutions may be commercialized independently by one or both parent companies once ready.

New products targeted for launch in the early 2030s

The venture builds on an existing multi-year partnership between the two companies. New solutions are expected to reach the market in the early 2030s through established commercial channels.

New York – – September 12, 2026 -- B&R Technology Merger Corp. (Nasdaq: BRTMU) will allow holders of its initial public offering units to separately trade Class A ordinary shares and warrants starting September 10, 2026.

Separated shares and warrants will trade under new Nasdaq tickers

Once split, the Class A ordinary shares will trade under the symbol "BRTM" and the warrants under "BRTMW" on the Nasdaq Stock Market. Units that remain unsplit will continue trading under the existing symbol "BRTMU."

No fractional warrants will be issued in the separation process

The company confirmed that only whole warrants will be tradable following separation, with no fractional warrant units created in the process.

Delray Beach, Fla. – September 08, 2026 -- The global clinical trial services market will grow from $66.20 billion in 2026 to $97.41 billion by 2031, expanding at a compound annual growth rate of 8.0%, according to MarketsandMarkets.

North America commands 45% of the market as CRO density drives outsourcing demand

North America held the largest regional share in 2025, roughly 45%, anchored by a dense concentration of contract research organizations and established pharmaceutical R&D spending. Phase III trials accounted for the largest service share in 2025 at approximately 39.5%, reflecting the higher volume of outsourced work their complexity demands. Small molecules led by modality with a 50.5% share in 2025, supported by a large installed pipeline of drug candidates.

Northbrook, Ill. – September 07, 2026 -- Hilco Real Estate, LLC is accepting bids until September 22 for a four-property portfolio along the Guadalupe River in the New Braunfels-Canyon Lake area of Texas, sold through a Chapter 11 bankruptcy process.

Bankruptcy sale offers assets individually or combined

The sale is directed by Gregory S. Milligan of Harney Partners as Chief Restructuring Officer for two jointly administered debtors, Kona Coast Venture, LTD and Hideout on the Horseshoe, LLC. The case is pending before the U.S. Bankruptcy Court for the Western District of Texas, San Antonio Division, under Case No. 26-51866. Buyers can pursue any single asset or combination, according to Hilco.

Delray Beach, Fla. – – September 07, 2026 -- The global concrete superplasticizers market is set to expand from USD 7.93 billion in 2026 to USD 10.54 billion by 2031, a 5.8% compound annual growth rate, according to MarketsandMarkets. Demand is being driven by rising infrastructure investment, ready-mix and precast concrete adoption, and the push to cut water use through polycarboxylate ether (PCE) polymer chemistry.

Middle East & Africa becomes the fastest-growing regional market at 6.6% CAGR

Saudi Arabia is the primary growth engine, with a future construction pipeline estimated at USD 1.52 trillion (SAR 5.7 trillion) in 2024, equal to 39% of the entire MENA region's pipeline. The Kingdom's Vision 2030 program requires more than 1.5 million housing units across five major cities by 2030, alongside transportation, energy, and tourism projects that depend on high-performance, durable concrete formulations.